Despite the broader market sell-off, Lupin, Sun Pharma, Torrent Pharma, CCL Products, and Karnataka Bank show remarkable resilience due to robust fundamentals like steady growth, strong pipelines, and strategic moves. Their performance suggests a potential for long-term leadership.

Karnataka Bank's share price dropped by 6%, trading at ₹217, following the release of Q4FY26 results. Despite a 7% year-on-year advance growth in the quarter, investors may be concerned about the bank's performance.

Karnataka Bank has announced a 4% year-on-year increase in deposits and a 7% year-on-year growth in advances for Q4, indicating steady expansion in both areas.

Karnataka Bank reports a 10% year-on-year increase in Current Account Savings Account (CASA) deposits, reaching ₹36,621 crore by the end of FY26. The bank's total deposits also grew by 3.8%, and gross advances expanded by 6.9% YoY, signaling steady growth in its financial position.

Karnataka Bank has successfully paid a Rs. 32.1 crore annual interest on its Tier II Bonds (INE614B08054), with no delays or compliance issues reported under SEBI regulations, as confirmed by the exchange.